-
Thematic Analysis
Oil and Gas M&A Deals 2023 – Top Themes – Thematic Intelligence
This report analyzes the disruptive themes that have driven M&A activity in 2023 in the Oil & Gas Sector
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Niraparib in Uveal Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Niraparib in Uveal Melanoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Niraparib in Uveal Melanoma Drug Details: Niraparib (MK-4827, Zejula) is an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Avapritinib in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Avapritinib in Solid Tumor Drug Details: Avapritinib (Ayvakit, Ayvakyt) is an anti-neoplastic agent. It is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HBM-1020 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HBM-1020 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. HBM-1020 in Solid Tumor Drug Details: HBM-1020 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HBM-1020 in Metastatic Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HBM-1020 in Metastatic Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. HBM-1020 in Metastatic Colorectal Cancer Drug Details: HBM-1020 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HBM-1020 in Metastatic Renal Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HBM-1020 in Metastatic Renal Cell Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. HBM-1020 in Metastatic Renal Cell Carcinoma Drug Details: HBM-1020...
-
Product Insights
Colon Carcinoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Colon Carcinoma - Drugs In Development, 2023’, provides an overview of the Colon Carcinoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Colon Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Neuroendocrine Carcinoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Neuroendocrine Carcinoma - Drugs In Development, 2023’, provides an overview of the Neuroendocrine Carcinoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Neuroendocrine Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Non-Small Cell Lung Carcinoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Non-Small Cell Lung Carcinoma - Drugs In Development, 2023’, provides an overview of the Non-Small Cell Lung Carcinoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Non-Small Cell Lung Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...